TABLE 1.
Characteristics of included studies.
| Study | Interventions | Number of patients | Number of women <%> | Follow-up | Mean age (years) |
|---|---|---|---|---|---|
| Akhyani et al. (2008) | Azithromycin vs. doxycycline <100 mg> | 67 | 30 <44.78> | 3 months | 47.93 |
| Bitar et al. (1990) | Placebo vs. metronidazole <1%> | 100 | 59 <59> | 8 weeks | 50.6 |
| Bjerke et al. (1989) | Placebo vs. metronidazole <1%> | 97 | 53 <54.6> | 60 days | 47 |
| Cai et al. (2002) | Placebo vs. metronidazole <0.75%> | 62 | 27 <43.55> | 12 weeks | 37 |
| Dahl et al. (2001) | Metronidazole <0.75> vs. metronidazole <1%> | 72 | 51 <70.8> | 12 weeks | 46 |
| Fowler et al. (2007) | Placebo vs. doxycycline <40 mg> | 72 | 56 <77.78> | 16 weeks | 47 |
| Gold et al. (2020) a | Placebo vs. minocycline <1.5%> | 751 | 541 <72.0> | 12 weeks | 49.2 |
| Gold et al. (2020) b | Placebo vs. minocycline <1.5%> | 770 | 533 <69.22> | 12 weeks | 50.9 |
| Huang et al. (2014) | Placebo vs. doxycycline <40 mg> | 170 | 121 <71.2> | 12 weeks | 49.1 |
| Koçak et al. (2002) | Placebo vs. metronidazole <0.75%> | 63 | 48 <80> | 60 days | 51 |
| Linden et al. (2017) | Doxycycline <40 mg> vs. minocycline <100 mg> | 80 | 59 <74> | 16 weeks | 46 |
| Marks et al. (1971) | Placebo vs. ampicillin vs. tetracycline | 56 | 29 <51.8> | 6 weeks | 47.8 |
| Martel et al. (2017) a | Placebo vs. clindamycin <0.3% Qd> vs. clindamycin <1% Bid> vs. clindamycin <1% Qd> | 416 | 311 <74.75> | 12 weeks | 47.9 |
| Martel et al. (2017) b | Placebo vs. clindamycin <1% Bid> | 213 | 147 <69.01> | 12 weeks | 48.12 |
| Miyachi et al. (2021) | Placebo vs. metronidazole <0.75%> | 130 | 107 <82.3> | 12 weeks | 47.8 |
| Monk et al. (1991) | Metronidazole <0.75%> vs. oxytetracycline | 33 | 16 <48.48> | 9 weeks | 49 |
| Mrowietz et al. (2018) | Placebo vs. minocycline <1.5%> vs. minocycline <3%> | 232 | 145 <62.5> | 12 weeks | 52.2 |
| NCT02840461 (2016) | Placebo vs. ivermectin | 630 | 449 71.3> | 12 weeks | 51.1 |
| NCT (2017) | Placebo vs. doxycycline <40 mg> vs. minocycline <20 mg> vs. minocycline <40 mg> | 205 | 124 <60.5> | 16 weeks | 50.5 |
| Nielsen (1983) a | Placebo vs. metronidazole <1%> | 81 | 49 <60.49> | 2 months | 47 |
| Nielsen (1983) b | Metronidazole <1%> vs. oxytetracycline | 51 | 34 <66.67> | 2 months | 44 |
| Rosso et al. (2007) | Placebo vs. doxycycline <40 mg> | 537 | 375 <69.8> | 16 weeks | 47.07 |
| Rosso et al. (2007) | Doxycycline <40 mg> vs. doxycycline <100 mg> | 91 | 64 <70.33> | 16 weeks | 44.76 |
| Rosso et al. (2020) | Placebo vs. doxycycline <40 mg> | 130 | 86 <66.15> | 40 weeks | 49.4 |
| Schachter et al. (1991) | Metronidazole <1%> vs. tetracycline | 125 | 61 <48.8> | 2 months | 45.4 |
| Schaller et al. (2020) | Placebo vs. doxycycline <40 mg> | 273 | 155 <56.78> | 12 weeks | 52 |
| Stein et al. (2014) | Placebo vs. ivermectin | 1,371 | 925 <67.5> | 12 weeks | 50.3 |
| Taieb et al. (2015) | Ivermectin vs. metronidazole <0.75%> | 962 | 627 <65.2> | 16 weeks | 51.54 |
| Veien et al. (1986) | Metronidazole <1%> vs. tetracycline | 76 | 39 <52> | 8 weeks | 52.4 |
| Verea et al. (1992) | Erythromycin vs. metronidazole <0.75%> | 40 | 27 <67.5> | 3 months | 59.78 |
| Webster et al. (2020) | Placebo vs. minocycline <1%> vs. minocycline <3%> | 270 | 189 <70> | 12 weeks | 51.1 |
Bid = twice a day; Qd = once a day; a/b represents different studies in one report.